Table 4 Multivariable Cox regression analyses of the related factors for developing various cancers in asthma patients.

From: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients

 

Model 1

Model 2

Model 3

LTRA users

cDDD ≤112

cDDD >112

cDDD(1y) ≤84

cDDD(1y) >84

HR [95% CI]

P value

HR [95% CI]

P value

HR [95% CI]

P value

HR [95% CI]

P value

HR [95% CI]

P value

Lung cancer

0.34 [0.20–0.60]

0.0002

0.43 [0.21–0.90]

0.0256

0.27 [0.12–0.62]

0.0019

0.32 [0.14–0.72]

0.0057

0.37 [0.18–0.78]

0.0094

Colorectal cancer

0.35 [0.20–0.62]

0.0004

0.43 [0.20–0.93]

0.0324

0.28 [0.12–0.66]

0.0037

0.42 [0.19–0.91]

0.0275

0.29 [0.12–0.68]

0.0045

Gastric cancer

0.30 [0.09–0.99]

0.0486

0.37 [0.08–1.71]

0.2040

0.21 [0.03–1.66]

0.1400

0.38 [0.08–1.72]

0.2087

0.21 [0.03–1.62]

0.1328

Liver cancer

0.34 [0.17–0.69]

0.0027

0.44 [0.18–1.08]

0.0738

0.24 [0.08–0.76]

0.0147

0.47 [0.20–1.10]

0.0806

0.19 [0.05–0.70]

0.0129

Pancreatic cancer

0.26 [0.05–1.44]

0.1220

0.24 [0.02–3.13]

0.2742

0.27 [0.03–2.42]

0.2426

0.20 [0.02–2.42]

0.2068

0.33 [0.03–3.50]

0.3553

Oral cancer

0.35 [0.12–1.01]

0.0519

0.32 [0.07–1.43]

0.1343

0.38 [0.08–1.72]

0.2093

0.32 [0.07–1.43]

0.1345

0.38 [0.08–1.72]

0.2100

Nasopharyngeal carcinoma

0.26 [0.03–2.51]

0.2470

‡

 

‡

 

‡

 

‡

 

Brain cancer

0.26 [0.03–2.51]

0.9974

‡

 

‡

 

‡

 

‡

 

Thyroid cancer

0.30 [0.06–1.55]

0.1504

‡

 

‡

 

‡

 

‡

 

Skin cancer

0.61 [0.15–2.53]

0.4964

0.67 [0.10–4.53]

0.6855

0.54 [0.06–4.79]

0.5797

0.71 [0.10–4.82]

0.7259

0.51 [0.06–4.49]

0.5453

Urinary cancer

0.78 [0.33–1.88]

0.5839

0.94 [0.32–2.77]

0.9112

0.55 [0.11–2.82]

0.4752

0.71 [0.22–2.24]

0.5550

0.92 [0.23–3.70]

0.9049

Breast cancer

0.09 [0.03–0.26]

<0.0001

0.15 [0.04–0.49]

0.0019

0.05 [0.01–0.34]

0.0025

0.09 [0.02–0.36]

0.0008

0.10 [0.02–0.44]

0.0022

Cervical cancer

0.48 [0.18–1.26]

0.1341

0.44 [0.12–1.60]

0.2129

0.52 [0.13–2.09]

0.3608

0.53 [0.17–1.64]

0.2718

0.38 [0.07–2.05]

0.2584

Prostate cancer

0.16 [0.03–0.94]

0.0419

0.19 [0.02–1.7]

0.1372

0.14 [0.01–1.74]

0.1265

0.16 [0.02–1.53]

0.1106

0.17 [0.01–2.34]

0.1873

  1. The results are presented with adjusted hazard ratios (HRs) (95% confidence interval) of LTRA users (model 1) or lower (cDDD ≤ 112 in model 2 and cDDD(1y) ≤ 84 in model 3) and higher (cDDD > 112 in model 2 and cDDD(1y) >84 in model 3) doses of LTRA use, using LTRA non-users as reference, which are adjusted for age, residency, income level, marriage status, education level and the presence of various comorbidities.
  2. The follow-up time was calculated from a year after the index date to either development of the specific cancer, death or the end of 2011, whichever came first.
  3. The cumulative defined daily doses of LTRA were calculated from the index date to the end of follow-up (cDDD) and to a year after the index date [cDDD(1y)].
  4. ‡The HR of some cancer types could not be estimated due to small sample size.
Back to article page